舒泰神(300204.SZ):“注射用STSP-0601”後續是否進入優先審評程序仍存在諸多不確定性
格隆匯5月29日丨舒泰神(300204.SZ)公佈股票交易嚴重異常波動公告,公司關注到近期市場對國家藥品監督管理局藥品審評中心(NMPA)網站信息公開欄目關於“擬優先審評品種公示”欄中公司控股子公司江蘇貝捷泰生物科技有限公司申請的“注射用STSP-0601”相關信息關注度較高;該藥品正處於公示期內,公示截止日期爲2025年06月03日,關於該藥品公示期滿後,後續是否進入優先審評程序仍存在諸多不確定性。敬請廣大投資者謹慎決策,注意防範投資風險。
公司多個在研項目屬於創新型生物製品。創新生物醫藥具有高科技、高風險、高附加值的特點,從研製、臨牀試驗、報批到投產的週期長、環節多,容易受到技術、審批、政策等諸多因素影響,面臨臨牀試驗進度可能不如預期、臨牀試驗結果可能不如預期、藥品申請上市批準可能不如預期等諸多風險,請廣大投資者謹慎決策,注意投資風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.